Roberto De Luca

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 27

Top Venues

Antibodies (Basel, Switzerland)

Pharmaceutics

Journal for immunotherapy of cancer

Molecular cancer therapeutics

Eidgenössische Technische Hochschule Zürich

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Eidgenössische Technische Hochschule Zürich Oct 01 2015 - Feb 28 2018

Switzerland

Ph.D. Student :: Departement Chemie und Angewandte Biowissenschaften

Publications

Cesare Di Nitto, Domenico Ravazza, Ettore Gilardoni, Thomas Look, Miaomiao Sun, Eleonora Prodi, Vlad Moisoiu, Christian Pellegrino, Markus G Manz, Emanuele Puca, Michael Weller, Tobias Weiss, Dario Neri, Roberto De Luca
An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade. Journal for immunotherapy of cancer 12 (8) (2024)
Abdullah Elsayed, Louis Plüss, Larissa Nideroest, Giulia Rotta, Marina Thoma, Nathan Sébastien Zangger, Frederik Peissert, Stefanie K Pfister, Christian Pellegrino, Sheila Dakhel, Roberto De Luca, Markus Gabriel Manz, Annette Oxenius, Emanuele Puca, Cornelia Halin, Dario Neri
Optimizing the Design and Geometry of T Cell-Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer. Molecular cancer therapeutics 23 (7) (2024)
Laura Lucaroni, Sebastian Oehler, Tony Georgiev, Marco Müller, Matilde Bocci, Roberto De Luca, Nicholas Favalli, Dario Neri, Samuele Cazzamalli, Luca Prati
DNA-encoded chemical libraries enable the discovery of potent PSMA-ligands with substantially reduced affinity towards the GCPIII anti-target. Chemical science 15 (18) (2024)
Cesare Di Nitto, Domenico Ravazza, Ettore Gilardoni, Thomas Look, Miaomiao Sun, Eleonora Prodi, Vlad Moisoiu, Christian Pellegrino, Markus G Manz, Emanuele Puca, Michael Weller, Tobias Weiss, Dario Neri, Roberto De Luca
An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade. Journal for immunotherapy of cancer 12 (8) (2024)
Abdullah Elsayed, Louis Plüss, Larissa Nideroest, Giulia Rotta, Marina Thoma, Nathan Sébastien Zangger, Frederik Peissert, Stefanie K Pfister, Christian Pellegrino, Sheila Dakhel, Roberto De Luca, Markus Gabriel Manz, Annette Oxenius, Emanuele Puca, Cornelia Halin, Dario Neri
Optimizing the design and geometry of T cell engaging bispecific antibodies targeting CEA in colorectal cancer. Molecular cancer therapeutics (2024)
Eleonora Prodi, Dario Neri, Roberto De Luca
Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy. OncoTargets and therapy 17 (2024)
Eleonora Prodi, Riccardo Corbellari, Lorenzo Ghezzi, Silvia Ciambellotti, Jacopo Elia Catastini, Marco Rappuoli, Giulia Rotta, Irma Sakic, Tobias Weiss, Michael Weller, Christian Pellegrino, Markus G Manz, Dario Neri, Roberto De Luca
Tripokin: A multi-specific immunocytokine for cancer immunotherapy. International journal of cancer (2024)
Laura Lucaroni, Sebastian Oehler, Tony Georgiev, Marco Müller, Matilde Bocci, Roberto De Luca, Nicholas Favalli, Dario Neri, Samuele Cazzamalli, Luca Prati
DNA-encoded chemical libraries enable the discovery of potent PSMA-ligands with substantially reduced affinity towards the GCPIII anti-target. Chemical science 15 (18) (2024)
Laura Volta, Renier Myburgh, Christian Pellegrino, Christian Koch, Monique Maurer, Francesco Manfredi, Mara Hofstetter, Anne Kaiser, Florin Schneiter, Jan Müller, Marco Matteo Bühler, Roberto De Luca, Nicholas Favalli, Chiara F Magnani, Timm Schroeder, Dario Neri, Markus Gabriel Manz
Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells. Leukemia (2024)
Cesare Di Nitto, Domenico Ravazza, Ettore Gilardoni, Thomas Look, Miaomiao Sun, Eleonora Prodi, Vlad Moisoiu, Christian Pellegrino, Markus G Manz, Emanuele Puca, Michael Weller, Tobias Weiss, Dario Neri, Roberto De Luca
An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade. Journal for immunotherapy of cancer 12 (8) (2024)
Eleonora Prodi, Claudia Comacchio, Ettore Gilardoni, Cesare Di Nitto, Emanuele Puca, Dario Neri, Roberto De Luca
An Antibody Targeting Fibroblast Activation Protein Simultaneously Fused to Interleukin-2 and Tumor Necrosis Factor Selectively Localizes to Neoplastic Lesions. Antibodies (Basel, Switzerland) 12 (2) (2023)
Eleonora Prodi, Claudia Comacchio, Ettore Gilardoni, Cesare Di Nitto, Emanuele Puca, Dario Neri, Roberto De Luca
An Antibody Targeting Fibroblast Activation Protein Simultaneously Fused to Interleukin-2 and Tumor Necrosis Factor Selectively Localizes to Neoplastic Lesions. Antibodies (Basel, Switzerland) 12 (2) (2023)
Eleonora Prodi, Claudia Comacchio, Ettore Gilardoni, Cesare Di Nitto, Emanuele Puca, Dario Neri, Roberto De Luca
An Antibody Targeting Fibroblast Activation Protein Simultaneously Fused to Interleukin-2 and Tumor Necrosis Factor Selectively Localizes to Neoplastic Lesions. Antibodies (Basel, Switzerland) 12 (2) (2023)
Cesare Di Nitto, Ettore Gilardoni, Jacqueline Mock, Lisa Nadal, Tobias Weiss, Michael Weller, Frauke Seehusen, Chiara Libbra, Emanuele Puca, Dario Neri, Roberto De Luca
An Engineered IFNγ-Antibody Fusion Protein with Improved Tumor-Homing Properties. Pharmaceutics 15 (2) (2023)
Cesare Di Nitto, Ettore Gilardoni, Jacqueline Mock, Lisa Nadal, Tobias Weiss, Michael Weller, Frauke Seehusen, Chiara Libbra, Emanuele Puca, Dario Neri, Roberto De Luca
An Engineered IFNγ-Antibody Fusion Protein with Improved Tumor-Homing Properties. Pharmaceutics 15 (2) (2023)
Cesare Di Nitto, Ettore Gilardoni, Jacqueline Mock, Lisa Nadal, Tobias Weiss, Michael Weller, Frauke Seehusen, Chiara Libbra, Emanuele Puca, Dario Neri, Roberto De Luca
An Engineered IFNγ-Antibody Fusion Protein with Improved Tumor-Homing Properties. Pharmaceutics 15 (2) (2023)
Eleonora Prodi, Claudia Comacchio, Ettore Gilardoni, Cesare Di Nitto, Emanuele Puca, Dario Neri, Roberto De Luca
An Antibody Targeting Fibroblast Activation Protein Simultaneously Fused to Interleukin-2 and Tumor Necrosis Factor Selectively Localizes to Neoplastic Lesions. Antibodies (Basel, Switzerland) 12 (2) (2023)
Eleonora Prodi, Claudia Comacchio, Ettore Gilardoni, Cesare Di Nitto, Emanuele Puca, Dario Neri, Roberto De Luca
An Antibody Targeting Fibroblast Activation Protein Simultaneously Fused to Interleukin-2 and Tumor Necrosis Factor Selectively Localizes to Neoplastic Lesions. Antibodies (Basel, Switzerland) 12 (2) (2023)
Cesare Di Nitto, Ettore Gilardoni, Jacqueline Mock, Lisa Nadal, Tobias Weiss, Michael Weller, Frauke Seehusen, Chiara Libbra, Emanuele Puca, Dario Neri, Roberto De Luca
An Engineered IFNγ-Antibody Fusion Protein with Improved Tumor-Homing Properties. Pharmaceutics 15 (2) (2023)
Abdullah Elsayed, Christian Pellegrino, Louis Plüss, Frederik Peissert, Ramon Benz, Franziska Ulrich, Gudrun Thorhallsdottir, Sheila Dakhel Plaza, Alessandra Villa, Jacqueline Mock, Emanuele Puca, Roberto De Luca, Markus Gabriel Manz, Cornelia Halin, Dario Neri
Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties. mAbs 15 (1) (2023)
Thomas Look, Emanuele Puca, Marcel Bühler, Daniel Kirschenbaum, Roberto De Luca, Riccardo Stucchi, Domenico Ravazza, Cesare Di Nitto, Patrick Roth, Yonatan Katzenelenbogen, Assaf Weiner, Lukas Rindlisbacher, Burkhard Becher, Bjørt K Kragesteen, Michael Weller, Dario Neri, Teresa Hemmerle, Tobias Weiss
Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell-dependent regression of glioblastoma. Science translational medicine 15 (697) (2023)
Lisa Nadal, Frederik Peissert, Abdullah Elsayed, Tobias Weiss, Thomas Look, Michael Weller, Geny Piro, Carmine Carbone, Giampaolo Tortora, Mattia Matasci, Nicholas Favalli, Riccardo Corbellari, Cesare Di Nitto, Eleonora Prodi, Chiara Libbra, Simone Galeazzi, Claudiopietro Carotenuto, Cornelia Halin, Emanuele Puca, Dario Neri, Roberto De Luca
Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody. Journal for immunotherapy of cancer 10 (9) (2022)
Cesare Di Nitto, Dario Neri, Tobias Weiss, Michael Weller, Roberto De Luca
Design and Characterization of Novel Antibody-Cytokine Fusion Proteins Based on Interleukin-21. Antibodies (Basel, Switzerland) 11 (1) (2022)
Lisa Nadal, Riccardo Corbellari, Alessandra Villa, Tobias Weiss, Michael Weller, Dario Neri, Roberto De Luca
Novel human monoclonal antibodies specific to the alternatively spliced domain D of Tenascin C efficiently target tumors in vivo. mAbs 12 (1) (2021)
Riccardo Corbellari, Marco Stringhini, Jacqueline Mock, Tiziano Ongaro, Alessandra Villa, Dario Neri, Roberto De Luca
A Novel Antibody-IL15 Fusion Protein Selectively Localizes to Tumors, Synergizes with TNF-based Immunocytokine, and Inhibits Metastasis. Molecular cancer therapeutics 20 (5) (2021)
Yizhou Li, Roberto De Luca, Samuele Cazzamalli, Francesca Pretto, Davor Bajic, Jörg Scheuermann, Dario Neri
Versatile protein recognition by the encoded display of multiple chemical elements on a constant macrocyclic scaffold. Nature chemistry 10 (4) (2018)
Roberto De Luca, Dario Neri
Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains. Cancer immunology, immunotherapy : CII 67 (9) (2018)

Roberto De Luca.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Roberto De Luca